vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.4倍（$217.4M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 1.4%，领先33.1%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 0.5%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $36.4M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 3.0%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
CPRX vs RPD — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $217.4M |
| 净利润 | $52.7M | $3.1M |
| 毛利率 | 82.9% | 68.9% |
| 营业利润率 | 40.5% | 1.0% |
| 净利率 | 34.5% | 1.4% |
| 营收同比 | 7.6% | 0.5% |
| 净利润同比 | -5.8% | 44.1% |
| 每股收益（稀释后） | $0.40 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $217.4M | ||
| Q3 25 | $148.4M | $218.0M | ||
| Q2 25 | $146.6M | $214.2M | ||
| Q1 25 | $141.4M | $210.3M | ||
| Q4 24 | $141.8M | $216.3M | ||
| Q3 24 | $128.7M | $214.7M | ||
| Q2 24 | $122.7M | $208.0M | ||
| Q1 24 | $98.5M | $205.1M |
| Q4 25 | $52.7M | $3.1M | ||
| Q3 25 | $52.8M | $9.8M | ||
| Q2 25 | $52.1M | $8.3M | ||
| Q1 25 | $56.7M | $2.1M | ||
| Q4 24 | $55.9M | $2.2M | ||
| Q3 24 | $43.9M | $15.4M | ||
| Q2 24 | $40.8M | $6.5M | ||
| Q1 24 | $23.3M | $1.4M |
| Q4 25 | 82.9% | 68.9% | ||
| Q3 25 | 84.7% | 70.2% | ||
| Q2 25 | 85.9% | 70.6% | ||
| Q1 25 | 87.3% | 71.7% | ||
| Q4 24 | 84.7% | 69.5% | ||
| Q3 24 | 85.0% | 70.6% | ||
| Q2 24 | 87.4% | 70.7% | ||
| Q1 24 | 87.3% | 70.3% |
| Q4 25 | 40.5% | 1.0% | ||
| Q3 25 | 44.7% | 2.7% | ||
| Q2 25 | 45.2% | 1.6% | ||
| Q1 25 | 44.8% | -0.0% | ||
| Q4 24 | 44.3% | 3.4% | ||
| Q3 24 | 39.6% | 6.0% | ||
| Q2 24 | 44.2% | 2.5% | ||
| Q1 24 | 27.5% | 4.7% |
| Q4 25 | 34.5% | 1.4% | ||
| Q3 25 | 35.6% | 4.5% | ||
| Q2 25 | 35.6% | 3.9% | ||
| Q1 25 | 40.1% | 1.0% | ||
| Q4 24 | 39.4% | 1.0% | ||
| Q3 24 | 34.1% | 7.2% | ||
| Q2 24 | 33.2% | 3.1% | ||
| Q1 24 | 23.6% | 0.7% |
| Q4 25 | $0.40 | $0.05 | ||
| Q3 25 | $0.42 | $0.15 | ||
| Q2 25 | $0.41 | $0.13 | ||
| Q1 25 | $0.45 | $0.03 | ||
| Q4 24 | $0.44 | $0.08 | ||
| Q3 24 | $0.35 | $0.21 | ||
| Q2 24 | $0.33 | $0.09 | ||
| Q1 24 | $0.19 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $154.7M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $474.7M | ||
| Q3 25 | $689.9M | $407.1M | ||
| Q2 25 | $652.8M | $511.7M | ||
| Q1 25 | $580.7M | $493.5M | ||
| Q4 24 | $517.6M | $521.7M | ||
| Q3 24 | $442.3M | $443.7M | ||
| Q2 24 | $375.7M | $442.6M | ||
| Q1 24 | $310.4M | $411.7M |
| Q4 25 | $954.3M | $154.7M | ||
| Q3 25 | $920.2M | $127.2M | ||
| Q2 25 | $856.0M | $90.4M | ||
| Q1 25 | $794.3M | $52.7M | ||
| Q4 24 | $727.6M | $17.7M | ||
| Q3 24 | $660.9M | $-5.1M | ||
| Q2 24 | $608.7M | $-52.6M | ||
| Q1 24 | $561.4M | $-86.4M |
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $971.9M | $1.6B | ||
| Q1 25 | $908.9M | $1.6B | ||
| Q4 24 | $851.4M | $1.7B | ||
| Q3 24 | $772.0M | $1.6B | ||
| Q2 24 | $706.4M | $1.5B | ||
| Q1 24 | $646.7M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $36.4M |
| 自由现金流率自由现金流/营收 | 29.4% | 16.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.85× | 12.01× |
| 过去12个月自由现金流最近4个季度 | — | $146.2M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $37.6M | ||
| Q3 25 | $32.4M | $39.0M | ||
| Q2 25 | $71.3M | $47.5M | ||
| Q1 25 | $60.0M | $29.8M | ||
| Q4 24 | $70.9M | $63.8M | ||
| Q3 24 | $72.9M | $44.0M | ||
| Q2 24 | $64.1M | $32.9M | ||
| Q1 24 | $31.9M | $31.1M |
| Q4 25 | $44.9M | $36.4M | ||
| Q3 25 | — | $34.8M | ||
| Q2 25 | $71.3M | $46.6M | ||
| Q1 25 | — | $28.4M | ||
| Q4 24 | $70.8M | $62.6M | ||
| Q3 24 | $72.6M | $42.6M | ||
| Q2 24 | $64.1M | $32.6M | ||
| Q1 24 | $31.7M | $30.4M |
| Q4 25 | 29.4% | 16.8% | ||
| Q3 25 | — | 16.0% | ||
| Q2 25 | 48.6% | 21.8% | ||
| Q1 25 | — | 13.5% | ||
| Q4 24 | 49.9% | 28.9% | ||
| Q3 24 | 56.4% | 19.9% | ||
| Q2 24 | 52.3% | 15.7% | ||
| Q1 24 | 32.2% | 14.8% |
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.1% | 0.5% | ||
| Q3 24 | 0.2% | 0.6% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.3% |
| Q4 25 | 0.85× | 12.01× | ||
| Q3 25 | 0.61× | 3.97× | ||
| Q2 25 | 1.37× | 5.70× | ||
| Q1 25 | 1.06× | 14.14× | ||
| Q4 24 | 1.27× | 29.36× | ||
| Q3 24 | 1.66× | 2.85× | ||
| Q2 24 | 1.57× | 5.03× | ||
| Q1 24 | 1.37× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
